Significant alterations in gene sequences, expression levels and protein structures have been associated with specific types of thyroid epithelial tumorigenesis. Recent revolutionary changes in molecular biology have spanned the disciplines of genomics and proteomics, which systematically generate and analyze the information about genomes, gene transcripts, proteins and their functions in a global, comprehensive manner. The application of these approaches will better discriminate between thyroid tumor subtypes that are not recognizable when traditional pathological criteria are used.
FournesB., MonierR., MichielsF., MilgromE., MisrahiM., FeunteunJ.: Oncogenic potential of a mutant human thyrotropin receptor expressed in FRTL-5 cells. Oncogene, 16: 985–990, 1998.
2.
AlbertiL., CarnitiC., MirandaC., RoccatoE., PierottiM.A.: RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol, 195: 168–186, 2003.
3.
BunoneG., UggeriM., MondelliniP., PierottiM.A., BongarzoneI.: RET receptor expression in thyroid follicular epithelial cell-derived tumors. Cancer Res, 60: 2845–2849, 2000.
4.
RamirezR., HsuD., PatelA., FentonC., DinauerC., TuttleR.M., FrancisG.L.: Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin Endocrinol (Oxf), 53: 635–644, 2000.
5.
EsapaC.T., JohnsonS.J., Kendall-TaylorP., LennardT.W., HarrisP.E.: Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf), 50: 529–535, 1999.
6.
KrollT.G., SarrafP., ChenC.J., MuellerE., SpiegelmanB.M., FletcherJ.A.: PAX8-PPARgammal fusion oncogene in human thyroid carcinoma. Science, 289: 1357–1360, 2000.
7.
CheungL., MessinaM., GillA., ClarksonA., LearoydD., DelbridgeL., WentworthJ., PhilipsJ., Clifton-BlighR., RobinsonB.G.: Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab, 88: 354–357, 2003.
8.
NikiforovaM.N., BiddingerP.W., CaudillC.M., KrollT.G., NikiforovY.E.: PAX8-PPAR gamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol, 26: 1016–1023, 2002.
9.
HuangY., PrasadM., LemonW.J., HampelH., WrightF.A., KornackerK., LiVolsiV., FrankelW., KloosR.T., EngC., PellegataN.S., de la ChapelleA.: Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA, 98: 15044–15049, 2001.
10.
WaseniusV.M., HemmerS., KettunenE., KnuutilaS., FranssilaK., JoensuuH.: Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res, 9: 68–75, 2003.
11.
GorgA., ObermaierC., BoguthG., HarderA., ScheibeB., WildgruberR., WeissW.: The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis, 21: 1037–1053, 2000.
12.
HanashS.M.: Biomedical applications of two-dimensional electrophoresis using immobilized pH gradients: current status. Electrophoresis, 21: 1202–1209, 2000.
